[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-364384-105":59,"doc-detail-364384-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","a-case-report-of-donor-cell-derived-hematologic-neoplasms-9-years-after-allogeneic-hematopoietic-cell-transplantation-case-report","A case report of donor cell-derived hematologic neoplasms 9 years after allogeneic hematopoietic cell transplantation - Case report","","Hematopoietic stem cell transplantation has transformed treatment of blood cancers, yet relapse remains a major challenge. In rare cases, new hematologic malignancies can arise from donor cells after HSCT, termed donor cell-derived hematologic neoplasms (DCHN). This report describes a patient treated with HSCT for acute myeloid leukemia who later developed triple-negative myeloproliferative neoplasms with ASXL1, SETBP1, and EZH2 mutations. Disease progression led to MDS/AML, and the patient died during induction therapy. Early diagnosis and timely intervention are emphasized due to the condition’s poor prognosis, and further research is needed to clarify pathogenesis and improve therapy.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/a-case-report-of-donor-cell-derived-hematologic-neoplasms-9-years-after-allogeneic-hematopoietic-cell-transplantation-case-report/364384/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/a-case-report-of-donor-cell-derived-hematologic-neoplasms-9-years-after-allogeneic-hematopoietic-cell-transplantation-case-report/364384.png","ImageObject",300,407,{"name":92,"@type":93},"Emma Wilson","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-12","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",15,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What are donor cell-derived hematologic neoplasms (DCHN) after HSCT?","Question",{"text":113,"@type":114},"DCHN are rare complications where donor hematopoietic cells undergo oncogenic transformation and develop hematologic malignancies after transplantation.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What diagnoses and genetic mutations were reported in this case?",{"text":118,"@type":114},"The patient developed triple-negative myeloproliferative neoplasms with mutations in ASXL1, SETBP1, and EZH2, later progressing to MDS/AML.",{"name":120,"@type":111,"acceptedAnswer":121},"How did the patient’s disease course end?",{"text":122,"@type":114},"The patient progressed over the following years and died during induction therapy, with symptoms including oedema, increasing shortness of breath, and infections.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},364384,1790808282,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":34,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},3848291630094,"https://eur-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","[www.oncotarget.com](www.oncotarget.com) Oncotarget, 2025, Vol. 16, pp: 44-50  \nCase Report  \nA case report of donor cell–derived hematologic neoplasms 9 years after allogeneic hematopoietic cell transplantation  \nAleksandra Mroczkowska-Bękarciak 1 and Tomasz Wróbel 1  \n1 Department and Clinic of Hematology, Cellular Therapies and Internal Medicine, Wroclaw Medical University, Wroclaw, Poland  \nCorrespondence to: Aleksandra Mroczkowska-Bękarciak, [email](email: omroczkowska@interia.pl)[: omroczkowska@interia.pl](email: omroczkowska@interia.pl), [https://orcid.org/0000-0002-8837-6517](https://orcid.org/0000-0002-8837-6517)[ ](https://orcid.org/0000-0002-8837-6517)[Keywords](Keywords: hematology)[: hematology](Keywords: hematology); donor cell-derived hematologic neoplasms; genetics  \nReceived: August 03, 2024 Accepted: January 21, 2025 Published: February 05, 2025  \nCopyright: © 2025 Mroczkowska-Bękarciak and Wróbel. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4 .0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.  \nABSTRACT  \nBackground: The treatment of blood cancers has been revolutionized by hematopoietic stem cell transplantation. Owing to this method, we are able to effectively treat most blood cancers. However, in some cases, one of the greatest problems is the risk of relapse. Most often, relapse of the disease manifests itself as cancer cells with the same characteristics as the primary cancer. Nevertheless, a very small percentage of patients develop other blood cancers from donor cells. Donor cell-derived hematologic neoplasms are extremely rare complications that arise after hematopoietic stem cell transplantation.  \nCase presentation: In this study we described a patient who underwent hematopoietic stem cell transplantation due to acute myeloid leukemia and subsequently developed triple-negative myeloproliferative neoplasms with mutations in the ASXL1, SETBP1 and EZH2 genes 9 years later. Over the next two years, the disease progressed and MDS/AML developed. Unfortunately, the patient died during induction therapy.  \nConclusions: Donor cell–derived hematologic neoplasms are rare but significant complications after HSCT. Early diagnosis and intervention are crucial to improving patient prognosis. Further studies are needed to better understand the pathogenesis of this condition and develop more effective therapeutic strategies.  \nINTRODUCTION  \nAn uncommon side effect of allogeneichematopoietic cell transplantation is donor cell-derived hematologic neoplasm (DCHN), which develops when donor hematopoietic cells undergo oncogenic transformation. Over the past decades, a growing number of cases of donor-derived leukemia have been documented in the literature since the initial report of the condition in 1971 [1] . The true frequency of DCHNs is unknown. The highest prevalence of DCHN was reported in 1982 by Boyd et [al. at](al. at) 1.2%[2]. Later reports have indicated that it was 0.84% by The Tokyo Cord Blood Bank [3] . 0.13% by the Japan Society for Hematopoietic Cell Transplantation [4] and 0.12% by the European Society for Blood and Marrow Transplantation (EBMT) since  \n2005 [5] . EBMT re-estimated the incidence of donor cell leukemia (DCL) in 2019, and a similar result of 0.1% was obtained [6]. Dietz et al. from the University of Minnesota found that, depending on the graft source, the incidence of DDL ranged from 0.53 to 0.56% at 15 years [7] . The increased use of molecular methods in hematological diagnostics facilitates the precise diagnosis of leukemias originating from donors. Therefore, there have been more reports about this interesting entity recently. The incidence of DCHN increased during a 30-year period from 0.2% to 0.7% according to a retrospective review of 1,994 allogeneic hematopoietic cell transplant recipients [8] . For alloHCT recipients, DCHN has ","cbCair8HCTuBADUy","https://ap.wps.com/l/cbCair8HCTuBADUy","pdf",554093,"English","# Abstract\n# Introduction\n# Case presentation","[{\"question\":\"What are donor cell-derived hematologic neoplasms (DCHN) after HSCT?\",\"answer\":\"DCHN are rare complications where donor hematopoietic cells undergo oncogenic transformation and develop hematologic malignancies after transplantation.\"},{\"question\":\"What diagnoses and genetic mutations were reported in this case?\",\"answer\":\"The patient developed triple-negative myeloproliferative neoplasms with mutations in ASXL1, SETBP1, and EZH2, later progressing to MDS/AML.\"},{\"question\":\"How did the patient’s disease course end?\",\"answer\":\"The patient progressed over the following years and died during induction therapy, with symptoms including oedema, increasing shortness of breath, and infections.\"}]","A case report of donor cell-derived hematologic neoplasms 9 years after allogeneic hematopoietic cell transplantation - Case report | PDF",1790157367,18,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/52420b2ce5e64355091baf8338766b03.webp",983,1272,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e974b3803a7c4a2d17f774085e03a111.webp",982,1270,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b39d980883c2720c4b38047bc66f96ec.webp",981,1269,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/599a2c04982dd354032a44bfa44a4dde.webp",980,1268]